(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 4.37% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Merck & Co's revenue in 2025 is $64,168,000,000.On average, 6 Wall Street analysts forecast MRK's revenue for 2025 to be $163,728,524,825,611, with the lowest MRK revenue forecast at $162,136,162,100,640, and the highest MRK revenue forecast at $165,093,948,454,781. On average, 6 Wall Street analysts forecast MRK's revenue for 2026 to be $173,523,177,299,450, with the lowest MRK revenue forecast at $168,636,686,494,982, and the highest MRK revenue forecast at $177,848,461,158,514.
In 2027, MRK is forecast to generate $184,507,208,884,821 in revenue, with the lowest revenue forecast at $177,007,432,548,623 and the highest revenue forecast at $192,268,136,951,654.